

BEACON PHARMACEUTICALS LTD.

153-154 Tejgan I/A., Dhaka-1208

STATEMENT OF FINANCIAL POSITION (Un-audited)

As at 31st March, 2015

Amount in Tk.

Particulars	31-Mar-15	30-Jun-14
ASSETS		
Non-Current Assets:		
Property, Plant & Equipments	1,965,931,700	2,218,349,300
Capital Work in Progress	207,905,064	202,471,300
Investment in Shares	11,646,959	11,646,959
Total Non-Current Assets	2,185,483,723	2,432,467,559
Current Assets:		
Inventories	1,168,021,215	1,064,947,942
Accounts Receivable	264,211,573	264,808,362
Advance, Deposit & Pre-payments	703,010,402	526,214,829
Short Term Investment	256,038,689	272,766,267
Cash & Cash Equivalants	83,185,042	28,620,341
Total Current Assets	2,474,466,921	2,157,357,741
TOTAL ASSETS	4,659,950,643	4,589,825,300
SHAREHOLDERS' EQUITY & LIABILITIES		
Shareholders' Equity:		
Paid up Capital	2,310,000,000	2,310,000,000
Reserve and Surplus	305,535,535	318,828,331
Retained Earning	266,728,261	238,553,678
Total Shareholders' Equity	2,882,263,796	2,867,382,009
Non-Current Liabilities:		
Long Term Loan:	676,679,684	660,360,017
	676,679,684	660,360,017
Current Liabilities:		
Short Term Loan	981,992,888	947,034,749
Current Portion of Long Term Loan	30,535,027	31,386,351
Share Application Money Refundable	4,650,411	4,656,093
Accounts Payable	30,065,330	31,109,038
Tax Payable	(3,009,562)	(11,313,361)
Accrued Expense	43,298,455	46,865,131
Vat Payable	152,892	565,044
Liabilities for EWF & WPPF	13,321,723	11,780,229
Total Current Liabilities	1,101,007,164	1,062,083,274
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES	4,659,950,643	4,589,825,300
Net Asset value (NAV) / Share	12.48	12.41
Par Value(Tk.)	10.00	10.00

Company Secretary

Managing Director

BEACON PHARMACEUTICALS LTD.

153-154 Tejgoan I/A., Dhaka-1208

STATEMENT OF COMPREHENSIVE INCOME (Un-audited)

For the 3rd Quarter ended 31st March, 2015

Particulars	July'14 to Mar'15	July'13 to Mar'14	Jan'15 to Mar'15	Amount in Tk.
	9 Months	9 Months	3rd Quarter	Jan'14 to Mar'14
Turnover (Net of VAT)	1,593,729,377	1,199,409,202	493,588,846	379,278,776
Less: Cost of Goods Sold	749,052,807	569,719,371	220,435,282	176,056,766
Gross Profit	844,676,570	629,689,831	273,153,564	203,222,010
Less: Administrative Expense	72,857,839	71,873,012	23,469,878	22,891,169
Less: Marketing, Selling & Distribution Exp.	575,219,772	403,424,588	180,209,572	114,866,933
Total Operating Expense	648,077,611	475,297,600	203,679,450	137,758,102
Operating Profit	196,598,959	154,392,231	69,474,114	65,463,908
Less: Financial Expense	177,572,384	170,759,477	59,062,718	64,045,257
Net Profit after Financial Expense	19,026,574	(16,367,246)	10,411,395	1,418,651
Income from other sources	5,013,235	32,077,566	946,082	3,142,339
Net Profit before IPO Expense	24,039,809	15,710,320	11,357,477	4,560,990
Less: Deferred IPO Expense	-	3,550,824	-	1,183,608
Net Profit before contribution to WPPF	24,039,809	12,159,496	11,357,477	3,377,382
Less: Contribution to WPPF	1,144,753	579,024	540,832	160,828
Net Profit before tax	22,895,056	11,580,472	10,816,645	3,216,554
Less: Income tax	8,013,270	4,342,677	3,785,826	1,206,207
Profit after tax	14,881,787	7,237,795	7,030,820	2,010,347
No of Shares	231,000,000	231,000,000	231,000,000	231,000,000
Earning Per Share	0.06	0.03	0.03	0.01

Company Secretary

Managing Director

BEACON PHARMACEUTICALS LTD.

153-154 Tejgoan I/A., Dhaka-1208

STATEMENT OF CHANGES IN EQUITY (Un-audited)

For the 3rd Quarter ended 31st March, 2015

Amount in Tk.

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Retained Earning	Total Equity
At the beginning of the year	2,310,000,000	313,325,232	5,503,099	238,553,678	2,867,382,009
Prior year adjustment	-	-	-	-	-
Net Profit (Loss) transferred from Income Statement	-	-	-	14,881,787	14,881,787
Revaluation Reserved adjustment	-	(13,292,796)	-	13,292,796	-
Transferred to Tax Holiday Reserve	-	-	-	-	-
Investment from Tax Holiday Reserve	-	-	-	-	-
Stock Dividend	-	-	-	-	-
Total	2,310,000,000	300,032,436	5,503,099	266,728,261	2,882,263,796

STATEMENT OF CHANGES IN EQUITY (Un-audited)

For the 3rd Quarter ended 31st March, 2014

Amount in Tk.

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Retained Earning	Total Equity
At the beginning of the year	2,310,000,000	331,048,960	5,503,099	126,706,269	2,773,258,328
Prior year adjustment	-	-	-	-	-
Net Profit (Loss) transferred from Income Statement	-	-	-	7,237,795	7,237,795
Revaluation Reserved adjustment	-	(13,292,796)	-	13,292,796	-
Transferred to Tax Holiday Reserve	-	-	-	-	-
Investment from Tax Holiday Reserve	-	-	-	-	-
Shares Issued during the year / Payment of Stock Dividend	-	-	-	-	-
Total	2,310,000,000	317,756,164	5,503,099	147,236,860	2,780,496,123

Company Secretary



Managing Director

BEACON PHARMACEUTICALS LTD.

153-154 Tejgoan I/A., Dhaka-1208

STATEMENT OF CASH FLOW (Un-audited)
For the 3rd Quarter ended 31st March, 2015

Particulars	Amount in Tk.	
	July'14 to Mar'15 9 Months	July'13 to Mar'14 9 Months
Cash Flows from Operating Activities:		
Collection against Sales	1,524,686,248	1,236,970,339
Payment to Creditors	(371,212,423)	(404,369,653)
Other Operating Expense	(957,395,680)	(664,468,291)
Interest Paid	(177,572,384)	(170,759,477)
Received from other sources	5,013,235	32,077,566
Net Cash Generated from Operating Activities	23,518,995	29,450,484
Cash Flows from Investing Activities		
Acquisition of Property, Plant & Equipments	(36,102,673)	(215,234,283)
Investment	16,727,578	(158,915,375)
Interest and Other Received	-	-
Net Cash Generated from Investing Activities	(19,375,095)	(374,149,658)
Cash Flows from Financing Activities		
Capital Received	-	-
Deferred IPO Expense	-	-
Excess Share Application Money Received	-	-
Excess Share Application Money Refund	(5,682)	-
Long Term Loan Received	165,409,343	-
Long Term Loan Refund	(149,941,000)	(84,190,667)
Short Term Loan Received	185,167,363	425,842,551
Short Term Loan Refund	(150,209,224)	-
Net Cash Generated from Financing Activities	50,420,800	341,651,884
Total Cash Flow	54,564,701	(3,047,290)
Cash and Cash Equivalent - Opening	28,620,341	7,673,698
Cash and Cash Equivalent - Closing	83,185,042	4,626,408
Operating Cash flow per Share	0.10	0.13
No of Shares Issued	231,000,000	231,000,000


Company Secretary
Managing Director

Notes to the Financial Position

For the 3rd quarter ended 31st March, 2015

1.00 Selected explanatory notes:

The financial statements have been prepared in line with accounting policies as adopted in the preparation of financial statements for the period ended 31st March, 2015. This interim financial report includes those selected explanatory notes as were deemed appropriate for the better understanding of the said un-audited financial statements.

2.00 Presentation of financial statements and basis of accounting:

The financial statements have been prepared in accordance with Generally Accepted Accounting Principles under Historical Cost Convention and after compliance with Bangladesh Financial Reporting Standard (BFRS) & Bangladesh Accounting Standard (BASs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

3.00 Property, Plant & Equipment:

3.01 Recognition and Measurement

Property, plant and equipment are capitalized at cost less accumulated depreciation in compliance with the requirements of BAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refunded taxes.

Fixed Assets as on 01.07.2014	3,237,988,813
Addition during the year	30,668,909
Total Assets	3,268,657,722
Less: Accumulated Depreciation as on 31.03.2015	1,302,726,022
Written Down Value as on 31.03.2015	1,965,931,700

4.00 Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: Inventories. Cost determined on weighted average cost basis. The cost of inventories comprises of expenditure in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale

4.01 Closing Stock

Raw Materials	337,156,650
Work-in-Process	45,286,150
Finished Goods	625,923,997
Packing Materials	83,660,938
Literature & Promotional Materials	21,976,055
Laboratory Chemicals	26,638,851
Stock of Stationery	6,445,662
Spares & Accessories	20,972,687
Balance as on 31st March, 2015	1,168,021,215

5.00 Cash and Cash Equivalents:

Cash and Cash equivalents includes cash in hand and with banks on current and deposit accounts which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

5.01 Cash and Cash Equivalents as on 31st March, 2015:

Cash in hand


Cash at Bank

Total Cash and Cash Equivalents:

5,396,197

77,788,845

83,185,042


Company Secretary


Managing Director